What is the recommended management of Kawasaki disease, including first‑line IVIG therapy, aspirin dosing, monitoring, and follow‑up?

Management of Kawasaki Disease

All patients with Kawasaki disease should receive intravenous immunoglobulin (IVIG) 2 g/kg as first-line therapy as soon as the diagnosis is made, ideally within 10 days of fever onset to prevent coronary artery abnormalities. 1

First-Line Treatment

IVIG Therapy

• Administer IVIG 2 g/kg as a single infusion as the cornerstone of acute KD treatment 1, 2
• Begin treatment promptly upon diagnosis, preferably within the first 10 days of illness 1
• Initial infusion rate should start at 0.01 mL/kg/minute (0.5 mg/kg/min) and can be increased to 0.10 mL/kg/minute (5 mg/kg/min) if tolerated 3
• For patients at risk of renal dysfunction or thrombosis, use the minimum infusion rate practicable 3

Aspirin Dosing

The evidence regarding aspirin dosing has evolved significantly, with recent high-quality studies challenging traditional high-dose regimens:

• Two dosing options are acceptable for initial therapy: 1

  • High-dose: 80-100 mg/kg/day divided into 4 doses until afebrile for 48 hours
  • Moderate-dose: 30-50 mg/kg/day divided into 4 doses until afebrile for 48 hours

• Recent evidence suggests IVIG alone may be non-inferior to IVIG plus aspirin: A 2025 multicenter randomized trial demonstrated that IVIG alone was non-inferior to IVIG plus high-dose aspirin for preventing coronary artery lesions (CAL occurrence: 1.5% vs 2.9% at 6 weeks, P=0.65) 4

• After the acute phase, transition to low-dose aspirin (3-5 mg/kg/day, single daily dose) and continue until follow-up echocardiograms confirm absence of coronary abnormalities, typically 6-8 weeks after disease onset 1, 5

Important caveat: Recent Japanese studies (2024) found no significant association between aspirin dose escalation above 30 mg/kg/day and prevention of coronary artery abnormalities, and doses below 30 mg/kg/day showed increased risk (OR 1.40 at 5 mg/kg/day) 6. Another 2024 study found no increased complications when ASA was omitted entirely in the acute phase 7.

Monitoring During Acute Phase

Cardiac Monitoring

• Obtain baseline echocardiogram at diagnosis to assess coronary arteries and cardiac function 1
• Repeat echocardiography at 2 weeks and 6-8 weeks after treatment initiation 1
• Monitor for signs of myocarditis, pericardial effusion, or valvular regurgitation 1

Laboratory Monitoring

• Monitor renal function (BUN, creatinine) before IVIG infusion and at appropriate intervals thereafter, particularly in patients at risk for renal dysfunction 3
• Assess inflammatory markers (CRP, ESR) to guide treatment response 1
• Monitor for hemolysis (hemoglobin, haptoglobin, direct antiglobulin test) as IVIG can cause hemolytic reactions 3

Clinical Monitoring

• Assess for persistent or recrudescent fever at least 36 hours after completion of initial IVIG infusion to identify IVIG-resistant patients 1
• Monitor for signs of thrombosis, particularly in patients with risk factors (advanced age, immobilization, hypercoagulable conditions) 3

Management of IVIG-Resistant Disease

IVIG resistance is defined as persistent or recrudescent fever ≥36 hours after completion of the first IVIG infusion. This occurs in approximately 10-15% of patients 5.

Second-Line Therapy Options

For IVIG-resistant patients, administer a second dose of IVIG 2 g/kg (Class IIa recommendation). 1

Alternative second-line options include: 1

• High-dose pulse methylprednisolone: 20-30 mg/kg IV daily for 3 consecutive days, with or without subsequent oral prednisone taper 1

  • Japanese studies showed this approach reduced fever duration and potentially coronary abnormalities compared to repeat IVIG 1

• Longer steroid course: 2-3 week tapering course of oral prednisolone (starting at 2 mg/kg/day) together with IVIG 2 g/kg, particularly for patients with recurrent fever after initial IVIG 1

  • This regimen may suppress persistent vascular inflammation more effectively than pulse steroids alone 1

• Infliximab 5 mg/kg IV: Administered over 2 hours as alternative to second IVIG dose 1

  • A phase I trial showed infliximab was well-tolerated with 90% response rate in IVIG-resistant patients 1
  • Retrospective data suggest shorter hospitalization and fewer fever days compared to repeat IVIG 1

Third-Line Therapy for Highly Refractory Disease

For patients who fail second-line therapy, consider: 1

• Cyclosporine: Oral dose of 4-6 mg/kg/day for highly refractory patients who have failed second IVIG, infliximab, or steroids 1

  • Monitor levels initially to establish appropriate dosing, then discontinue monitoring 1
  • Taper by 10% every 3 days once afebrile with CRP ≤1.0 mg/dL or after 2 weeks of therapy 1
  • Small studies showed 64-78% response rate with few serious adverse effects 1

• Anakinra (IL-1 receptor antagonist): Case reports describe successful use in highly refractory cases, though clinical trials are ongoing 1

• Plasma exchange: Reserved only for patients in whom all reasonable medical therapies have failed due to associated risks 1

• Cytotoxic agents (cyclophosphamide): Used in conjunction with oral steroids for exceptional patients with particularly refractory disease 1

High-Risk Patients Requiring Adjunctive Therapy

For patients with high-risk features for IVIG resistance or coronary artery aneurysms, consider adding adjunctive corticosteroids to initial IVIG therapy (conditional recommendation) 2, 8:

• Japanese RAISE study demonstrated that adjunctive prednisolone reduced coronary artery dilation in high-risk patients 8
• Risk stratification scores (e.g., Kobayashi score) can identify patients who may benefit from intensified initial therapy 8

Long-Term Follow-Up

Patients Without Coronary Abnormalities

• Continue low-dose aspirin (3-5 mg/kg/day) until echocardiograms at 6-8 weeks confirm no coronary abnormalities 1, 5
• Repeat echocardiography at 2 weeks and 6-8 weeks after disease onset 1
• No long-term cardiac restrictions if coronaries remain normal 9

Patients With Coronary Artery Abnormalities

• Mild-to-moderate coronary abnormalities: Continue antiplatelet therapy with low-dose aspirin (3-5 mg/kg/day) or clopidogrel (1 mg/kg/day up to 75 mg) 5

• Giant coronary aneurysms (≥8 mm) or multiple aneurysms: Require combination therapy with antiplatelet agent PLUS anticoagulation (warfarin or low-molecular-weight heparin) 5

• More frequent echocardiographic surveillance and potential stress testing or coronary angiography based on severity 9

Critical Safety Considerations

IVIG-Related Complications

• Thrombosis risk: Ensure adequate hydration before IVIG administration; monitor patients with cardiovascular risk factors, advanced age, or hypercoagulable states 3
• Renal dysfunction: Avoid volume depletion in patients with pre-existing renal insufficiency; discontinue IVIG if renal function deteriorates 3
• Aseptic meningitis: Can occur within several hours to 2 days after IVIG, particularly with high doses or rapid infusion 3
• Hemolysis: Monitor for signs of intravascular hemolysis or enhanced RBC sequestration, especially with high doses and non-O blood groups 3
• TRALI (transfusion-related acute lung injury): Monitor for pulmonary adverse reactions 3

Aspirin-Related Considerations

• Avoid aspirin in patients with active varicella or influenza due to Reye syndrome risk 1
• Monitor for bleeding complications, particularly in patients with thrombocytopenia 1

Vaccination Considerations

• IVIG may interfere with live viral vaccine response (measles, mumps, rubella, varicella) for up to 11 months after administration 3
• Delay live virus vaccination or revaccinate as appropriate 3